Current problems in cancer. Case reports最新文献_第4页

Alpelisib (phosphatidylinositol 3-kinase inhibitor) induced uncontrolled hyperglycemia and colitis Alpelisib（磷脂酰肌醇3-激酶抑制剂）诱发失控性高血糖和结肠炎

Current problems in cancer. Case reports Pub Date : 2024-05-22 DOI: 10.1016/j.cpccr.2024.100294

Sanchit Duhan , Nadeem Tabbara , Bijeta Keisham , Nymisha Boddeti , Daniel A. Laheru

{"title":"Alpelisib (phosphatidylinositol 3-kinase inhibitor) induced uncontrolled hyperglycemia and colitis","authors":"Sanchit Duhan , Nadeem Tabbara , Bijeta Keisham , Nymisha Boddeti , Daniel A. Laheru","doi":"10.1016/j.cpccr.2024.100294","DOIUrl":"https://doi.org/10.1016/j.cpccr.2024.100294","url":null,"abstract":"<div><p>Alpelisib is currently the only Phosphatidylinositol 3-kinase (PI3K) inhibitor approved for treating endocrine therapy-resistant metastatic breast cancer with a Phosphatidylinositol-4,5-bisphosphonate 3-kinase catalytic subunit alpha (PIK3CA)-mutation. Significant side effects of treatment include hepatotoxicity, hyperglycemia, diarrhea, nausea, stomatitis, fatigue, anorexia, and rash. We discuss the case of a 71-year-old woman with PI3K-mutated metastatic breast cancer and diabetes who presented with abdominal pain, nausea, and anorexia. She was started on alpelisib 250 mg daily four days before the hospital presentation. Notable labs at presentation included a glucose of 537 mg/dL and intrinsic renal acute kidney injury (AKI) with a creatinine of 1.6 mg/dL (baseline 1.2–1.3 mg/dL). A Computed Tomography (CT) scan was suggestive of typhlitis/colitis. After excluding other causes of hyperglycemia, she was diagnosed with alpelisib-induced hyperglycemia. Hyperglycemia with alpelisib is often severe and should prompt immediate consultation with endocrinology. Sodium-glucose co-transporter (SGLT) -2 inhibitors have been the most studied. However, concurrent kidney injuries may limit their real-world application. Alpelisib-associated complications subjected our patient to additional imaging, antibiotics, and prolonged hospital stay (6 days). The overall survival is not significantly increased with alpelisib as per the currently available data. More prospective trials will help assess and balance this drug's safety/efficacy profile to achieve better outcomes.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000176/pdfft?md5=f6aba6ed2552a9ca1b2a17d2044f679d&pid=1-s2.0-S2666621924000176-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141077874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advanced non-small cell lung cancer patient with a complete response and allergic immune-related adverse events by combined immunotherapy, including anti-CTLA-4 and anti-PD-1 antibodies: A case report 晚期非小细胞肺癌患者通过联合免疫疗法（包括抗 CTLA-4 和抗 PD-1 抗体）获得完全应答并出现过敏性免疫相关不良反应：病例报告

Current problems in cancer. Case reports Pub Date : 2024-05-19 DOI: 10.1016/j.cpccr.2024.100298

Chiho Nakashima , Yuki Kuwahara , Syo Kitamura , Keita Kai , Masafumi Hiratsuka , Kokoro Kajiwara , Natsuko Komiya , Shinsuke Ogusu , Shinya Kimura , Naoko Sueoka-Aragane

{"title":"Advanced non-small cell lung cancer patient with a complete response and allergic immune-related adverse events by combined immunotherapy, including anti-CTLA-4 and anti-PD-1 antibodies: A case report","authors":"Chiho Nakashima , Yuki Kuwahara , Syo Kitamura , Keita Kai , Masafumi Hiratsuka , Kokoro Kajiwara , Natsuko Komiya , Shinsuke Ogusu , Shinya Kimura , Naoko Sueoka-Aragane","doi":"10.1016/j.cpccr.2024.100298","DOIUrl":"https://doi.org/10.1016/j.cpccr.2024.100298","url":null,"abstract":"<div><p>Immune checkpoint inhibitors (ICIs) are indispensable agents that may improve the long-term prognosis of non-small cell lung cancer. However, clinicians should always be aware that its immune-modulating mechanism of action may lead to unexpected immune-related adverse events (irAE). We report here a case of a 72-year-old man with adenocarcinoma of the lung who achieved a complete response to nivolumab plus ipilimumab plus chemotherapy but also suffered from a variety of immune-related adverse events. In this patient, Th1 immunity, which is involved in antitumor immunity, and Th2 immunity were activated, resulting in allergy-related reactions, including increased airway hyperresponsiveness and a marked increase in serum IgE levels. After starting corticosteroids, the allergic symptoms were well controlled. Remarkably, despite discontinuing ICI treatment, the patient has maintained a complete response for 27 months. Fortunately, we obtained lung and lymph node tissues from this patient after ICI administration and histologically examined the Th1 and Th2 immune status.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000218/pdfft?md5=5986a42e2b6da6b36d5f1db3b63fca88&pid=1-s2.0-S2666621924000218-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141072790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acro metastasis: A rare presentation in a common cancer 骨转移：常见癌症中的罕见表现

Current problems in cancer. Case reports Pub Date : 2024-05-18 DOI: 10.1016/j.cpccr.2024.100292

Ali Ghanei-Shahmirzadi , Nasrin Namdari , Maral Mokhtari , Pooya Iranpour

引用次数: 0

Inflammation of actinic keratoses after the use of docetaxel plus cyclophosphamide 使用多西他赛+环磷酰胺后光化性角化病的炎症反应

Current problems in cancer. Case reports Pub Date : 2024-05-15 DOI: 10.1016/j.cpccr.2024.100293

Ashley Wittmer , Lindsey Finklea , Jonathan Joseph

{"title":"Inflammation of actinic keratoses after the use of docetaxel plus cyclophosphamide","authors":"Ashley Wittmer , Lindsey Finklea , Jonathan Joseph","doi":"10.1016/j.cpccr.2024.100293","DOIUrl":"10.1016/j.cpccr.2024.100293","url":null,"abstract":"<div><p>Actinic keratoses are common pre-malignant lesions of the skin that have been documented to become inflamed after the use of chemotherapy. Several agents, such as 5-fluorouracil, capecitabine, pentostatin, dactinomycin, vincristine, dacarbazine, cytarabine, 6-thioguanine, sorafenib, paclitaxel, and docetaxel have been documented to cause this reaction. This case report aims to describe the inflammation of actinic keratoses in response to docetaxel plus cyclophosphamide. A 64-year-old woman undergoing chemotherapy for breast cancer presented to the clinic with multiple scaly, erythematous papules covering her shoulders, arms, chest, and back. This occurred 15 days after treatment with IV docetaxel plus cyclophosphamide. The results of the shave biopsies done at the visit were consistent with inflammation. She was treated with topical triamcinolone ointment and the inflammation greatly improved within one month. The inflammation was completely resolved two months after completing therapy with docetaxel plus cyclophosphamide. Documentation of cutaneous adverse events help provide awareness of this reaction and thereby prevent cessation of necessary cancer treatments. Further research is needed to determine which patients undergoing chemotherapy may be susceptible to inflammation of actinic keratoses.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000164/pdfft?md5=b2323e149187f056d021ab472e000e66&pid=1-s2.0-S2666621924000164-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141040979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Co-Occurrence of ALK rearrangement and KRAS G12C mutation in NSCLC: Report of two cases 在 NSCLC 中同时出现 ALK 重排和 KRAS G12C 突变：两个病例的报告

Current problems in cancer. Case reports Pub Date : 2024-05-11 DOI: 10.1016/j.cpccr.2024.100291

M Siringo , F Larocca , A Spagnuolo , G Gentile , M Anile , D Diso , D Santini , A Gelibter

{"title":"Co-Occurrence of ALK rearrangement and KRAS G12C mutation in NSCLC: Report of two cases","authors":"M Siringo , F Larocca , A Spagnuolo , G Gentile , M Anile , D Diso , D Santini , A Gelibter","doi":"10.1016/j.cpccr.2024.100291","DOIUrl":"https://doi.org/10.1016/j.cpccr.2024.100291","url":null,"abstract":"<div><p>In the last few years, non-small cell lung cancer (NSCLC) treatment has totally revolutionized by the improvement in molecular diagnostics and the introduction of targeted therapies, becoming the standard of care in patients with actionable alterations. Mostly, genomic mutations are mutually exclusive although some cases of co-occurring actionable alterations could be discovered, especially with the recent introduction of genomic sequencing by next generation sequencing (NGS). Few data are available in the treatment of these particular cases. The co-occurring RAS G12C mutation seems to be a poor prognostic factor in patients with ALK rearranged NSCLC. We report two cases of women with diagnosis of advanced adenocarcinoma oncogene addicted with ALK rearrangement and KRAS G12C mutation. In both cases the PD-L1 status was high (> 50 %). Although both received Alectinib as ALK inhibitor, the lesion rapidly progressed. The patients had benefit only by treatments with chemotherapy, while anti PD-1/PD-L1 axis inhibitors seemed to be inefficient. Precise diagnostic techniques allow the detection of concomitant driver alterations; therefore, oncologists should consider these rare double mutations in NSCLC patients. Further prospective study is still warranted to investigate the role of co-occurring driver alterations and the relevant treatment paradigm</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000140/pdfft?md5=24447c841c93e8461976d6677b722c8b&pid=1-s2.0-S2666621924000140-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140918555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The use of ctDNA MRD precision medicine surveillance after definitive treatment of early-stage, high-risk breast cancer in a radiation oncology practice: A case series 放射肿瘤学实践中早期高危乳腺癌确诊治疗后ctDNA MRD精准医学监测的应用：病例系列

Current problems in cancer. Case reports Pub Date : 2024-05-11 DOI: 10.1016/j.cpccr.2024.100295

Michael A. Durka , Eemon Tizpa , Brian D. Lawenda

{"title":"The use of ctDNA MRD precision medicine surveillance after definitive treatment of early-stage, high-risk breast cancer in a radiation oncology practice: A case series","authors":"Michael A. Durka , Eemon Tizpa , Brian D. Lawenda","doi":"10.1016/j.cpccr.2024.100295","DOIUrl":"10.1016/j.cpccr.2024.100295","url":null,"abstract":"<div><p>Standard of care for patients with early-stage breast cancer typically does not use systemic surveillance or imaging studies following the administration of definitive treatment. However, the use of a circulating tumor DNA (ctDNA) test may provide an opportunity for early detection of cancer recurrence, particularly in patients with high-risk or aggressive forms of the disease. We present two cases of early-stage triple-negative breast cancer (TNBC) in which ctDNA screening facilitated early detection of recurrence prior to detection by imaging. As a result, treatment was initiated sooner than would have been possible in the absence of ctDNA screening.</p><p>These cases underscore the potential utility of ctDNA screening integration within a radiation oncology practice for the detection of recurrent breast cancer, and how their use in routine clinical practice could benefit patients. We also provide a review of the current literature on ctDNA testing, including its benefits and limitations. While there is currently insufficient data to support the routine use of ctDNA screening in all patients, we speculate on specific patient populations that may derive the greatest benefit from this innovative diagnostic tool.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000188/pdfft?md5=66906b35790af2ba622b686341d79661&pid=1-s2.0-S2666621924000188-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141042517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Combination pembrolizumab and lenvatinib in metastatic mismatch repair deficient adenocarcinoma of Mullerian origin: A case report Pembrolizumab和仑伐替尼联合治疗转移性错配修复缺陷缪勒源性腺癌：病例报告

Current problems in cancer. Case reports Pub Date : 2024-05-10 DOI: 10.1016/j.cpccr.2024.100297

Jessica M. Velasquez, Matthew Flint, Caitlin Carr, Samantha Cohen

{"title":"Combination pembrolizumab and lenvatinib in metastatic mismatch repair deficient adenocarcinoma of Mullerian origin: A case report","authors":"Jessica M. Velasquez, Matthew Flint, Caitlin Carr, Samantha Cohen","doi":"10.1016/j.cpccr.2024.100297","DOIUrl":"10.1016/j.cpccr.2024.100297","url":null,"abstract":"<div><h3>Background</h3><p>For mismatch repair protein deficient (dMMR) endometrial cancer (EC), first line therapy remains platinum-based chemotherapy. For dMMR EC that has progressed on standard first line platinum containing chemotherapy, treatment with programmed death ligand-1 (PD-1) inhibitors such as pembrolizumab have become integral to second line therapy. The challenging question remains, however, what the next best step is when these treatments fail.</p></div><div><h3>Case</h3><p>Here we report the case of a 71-year-old female who developed disease recurrence more than 20 years after surgical treatment for early stage dMMR endometrioid EC, with subsequent progression of disease on second line pembrolizumab therapy; however displayed excellent response to third line treatment with lenvatinib and pembrolizumab.</p></div><div><h3>Conclusion</h3><p>Consensus regarding third line treatment for patients with dMMR EC who progress on single agent PD-1 inhibitors after platinum-based chemotherapy failure remains unclear. While single agent pembrolizumab has demonstrated the greatest efficacy for dMMR disease, this case demonstrates a patient who had progression of disease on single agent pembrolizumab, however had excellent response with combination pembrolizumab and lenvatinib. Further study is warranted to assess the efficacy of this regimen for advanced or recurrent dMMR EC.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000206/pdfft?md5=53ec6027d213bdcae4889c6a034bcb38&pid=1-s2.0-S2666621924000206-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141044418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rare case of epithelioid angiosarcoma presenting as nodular pulmonary opacities in a 23-year-old woman 一名 23 岁女性罕见的上皮样血管肉瘤结节性肺不张病例

Current problems in cancer. Case reports Pub Date : 2024-04-21 DOI: 10.1016/j.cpccr.2024.100290

Zein Kattih , Jonathan Moore , Alain Borczuk , Ann E. Tilley

引用次数: 0

Simultaneous PTHrp- and calcitriol-mediated hypercalcemia associated with probable spontaneous transformation of lung adenocarcinoma to squamous cell carcinoma: A case report 同时由 PTHrp 和降钙素三醇介导的高钙血症与肺腺癌可能自发转化为鳞癌有关：病例报告

Current problems in cancer. Case reports Pub Date : 2024-04-15 DOI: 10.1016/j.cpccr.2024.100289

Run Yu

{"title":"Simultaneous PTHrp- and calcitriol-mediated hypercalcemia associated with probable spontaneous transformation of lung adenocarcinoma to squamous cell carcinoma: A case report","authors":"Run Yu","doi":"10.1016/j.cpccr.2024.100289","DOIUrl":"https://doi.org/10.1016/j.cpccr.2024.100289","url":null,"abstract":"<div><p>Hypercalcemia is a common paraneoplastic syndrome. Malignancies cause hypercalcemia by various mechanisms. Usually a single mechanism underlies paraneoplastic hypercalcemia. Two simultaneous mechanisms associated with one malignancy, however, are occasionally encountered. Here a rare case is reported to describe simultaneous PTHrp- and calcitriol-mediated hypercalcemia associated with probable spontaneous transformation of lung adenocarcinoma to squamous cell carcinoma. This 81-year-old male with history of resected lung adenocarcinoma developed hypercalcemia. The peak albumin-corrected calcium was 13.4 mg/dL (normal 8.6–10.4) with ionized calcium 1.70 mmol/L (normal 1.09–1.29). Laboratory tests showed PTH 7 pg/ml (normal 11–51), PTHrP 43.7 pmol/L (normal <2.3), 25-hydroxyvitamin D 33 ng/ml (normal 20–50), 1,25-dihydroxyvitamin D 71.0 pg/ml (19.9–79.3), TSH 3.1 µIU/mL (normal 0.3–4.7). CT showed new right lower lobe lung masses, paraesophageal and pericaval lymph nodes, and a cranial lesion. Biopsy of a lung mass revealed predominantly squamous cell carcinoma. He was treated with intravenous fluid and zoledronate with normalization of calcium levels. Vitamin D supplement was discontinued. The patient's clinical condition deteriorated before chemotherapy was started. He died shortly after comfort care was initiated. Pursuing multiple causes of paraneoplastic hypercalcemia is worthwhile as the treatment towards each mechanism is different.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000127/pdfft?md5=cedc7f8438be9a1bb9c951b6b5166d87&pid=1-s2.0-S2666621924000127-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140554082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenges in managing chronic kidney disease with simultaneous renal transplant immunosuppressant induced buccal squamous cell carcinoma and gastric Burkitt's like lymphoma: A case report 同时患有肾移植免疫抑制剂诱发的口腔鳞状细胞癌和胃伯基特样淋巴瘤的慢性肾病患者的治疗挑战：病例报告

Current problems in cancer. Case reports Pub Date : 2024-04-04 DOI: 10.1016/j.cpccr.2024.100288

Syeda Sara Tajammul , Shruti Maheshwari , Javeria Munir , Khalil Al-Farsi , Ali Allawati , Zamzam Al Hashami , Layth Mula-Hussain

{"title":"Challenges in managing chronic kidney disease with simultaneous renal transplant immunosuppressant induced buccal squamous cell carcinoma and gastric Burkitt's like lymphoma: A case report","authors":"Syeda Sara Tajammul , Shruti Maheshwari , Javeria Munir , Khalil Al-Farsi , Ali Allawati , Zamzam Al Hashami , Layth Mula-Hussain","doi":"10.1016/j.cpccr.2024.100288","DOIUrl":"https://doi.org/10.1016/j.cpccr.2024.100288","url":null,"abstract":"<div><p>Immunodeficiency is associated with higher cancer incidence, especially in transplanted patients; however, it is unknown whether there is a link between immunodeficiency and the development of multiple primary malignancies. Immunosuppressive drugs may either indirectly potentiate the effect of carcinogens or directly damage the DNA. Skin cancers are the most common malignancies diagnosed in renal transplant recipients. Management of immunosuppression in recipients of transplants who are living with cancer is complex and challenging. A concerted approach between transplant professionals, oncologists, and allied health professionals is therefore needed to ensure optimal care for transplant recipients who are developing immunodeficiency-induced malignancies. Here, we report a challenging case that presented with two simultaneous malignancies (buccal squamous cell carcinoma and gastric Burkitt's-like lymphoma) after nine years of being on immunosuppressants after the kidney transplant. The patient tolerated his cancer treatments with some grade II-III toxicities and is currently a two-year disease-free survivor. Focusing on the curative intent approaches for the two cancers with the adjustment of the immunosuppressant medications, besides the complications associated with these radical treatments, is worthy of being presented to the transplant and oncology teams globally.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000115/pdfft?md5=848d60d4cfd716d236f3f30a83a3b20e&pid=1-s2.0-S2666621924000115-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140533884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0